Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C15H17ClFNO4S |
| Molecular Weight | 361.816 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)NC2=CC=C(F)C=C2Cl
InChI
InChIKey=LEEIJTHMHDMWLJ-CQSZACIVSA-N
InChI=1S/C15H17ClFNO4S/c1-2-22-15(19)11-5-3-4-6-14(11)23(20,21)18-13-8-7-10(17)9-12(13)16/h5,7-9,14,18H,2-4,6H2,1H3/t14-/m1/s1
| Molecular Formula | C15H17ClFNO4S |
| Molecular Weight | 361.816 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Resatorvid (TAK-242) is a Toll-like receptor 4 (TLR4) antagonist that was designed for the treatment of severe sepsis because of its inhibitory effect on suppressing cytokine levels. This compound suppresses production of inflammatory mediators by inhibiting signal transduction through TLR4. It has also been shown that topical resatorvid, in a UV-induced skin tumorigenesis model, displays photochemopreventive activity, suppressing tumor area and multiplicity. Resatorvid has furthermore shown neuroprotective effects after traumatic brain injury (in a mouse model). Phase III studies evaluating the effects of resatorvid on sepsis have been completed. One such study was ended after it was determined that there was insufficient cytokine suppression in the first stage of the study.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL5255 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18299127 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
54.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25586141/ |
3 mg/kg bw single, intraperitoneal dose: 3 mg/kg bw route of administration: Intraperitoneal experiment type: SINGLE co-administered: |
RESATORVID plasma | Mus musculus population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
6.08 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21950150/ |
3 mg/kg single, intravenous dose: 3 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
RESATORVID plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FED |
|
1322 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21950150/ |
3 mg/kg single, intravenous dose: 3 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
RESATORVID plasma | Canis lupus population: HEALTHY age: ADULT sex: MALE food status: FED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
5.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21950150/ |
3 mg/kg single, intravenous dose: 3 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
RESATORVID plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FED |
|
158 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21950150/ |
3 mg/kg single, intravenous dose: 3 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
RESATORVID plasma | Canis lupus population: HEALTHY age: ADULT sex: MALE food status: FED |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Involvement of L-type Ca²⁺ channel and toll-like receptor-4 in nickel-induced interleukin-8 gene expression. | 2016-01 |
|
| The immunobiology of cobalt: demonstration of a potential aetiology for inflammatory pseudotumours after metal-on-metal replacement of the hip. | 2014-09 |
|
| Pro-inflammatory and pro-oxidant status of pancreatic islet in vitro is controlled by TLR-4 and HO-1 pathways. | 2014 |
|
| Crucial role of Toll-like receptors in the zinc/nickel-induced inflammatory response in vascular endothelial cells. | 2013-12-15 |
|
| Calcineurin inhibitors recruit protein kinases JAK2 and JNK, TLR signaling and the UPR to activate NF-κB-mediated inflammatory responses in kidney tubular cells. | 2013-11-01 |
|
| Lipopolysaccharide potentiates polychlorinated biphenyl-induced disruption of the blood-brain barrier via TLR4/IRF-3 signaling. | 2012-12-16 |
|
| Lipopolysaccharide induces H1 receptor expression and enhances histamine responsiveness in human coronary artery endothelial cells. | 2011-04 |
|
| Toll-like receptors in the pathogenesis of alcoholic liver disease. | 2010 |
|
| Toll-like receptor 4 modulation as a strategy to treat sepsis. | 2010 |
|
| Discovery and development of toll-like receptor 4 (TLR4) antagonists: a new paradigm for treating sepsis and other diseases. | 2008-08 |
|
| Bench-to-bedside review: sepsis, severe sepsis and septic shock - does the nature of the infecting organism matter? | 2008 |
|
| A novel cyclohexene derivative, ethyl (6R)-6-[N-(2-Chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1-carboxylate (TAK-242), selectively inhibits toll-like receptor 4-mediated cytokine production through suppression of intracellular signaling. | 2006-04 |
|
| Optically active cyclohexene derivative as a new antisepsis agent: an efficient synthesis of ethyl (6R)-6-[N-(2-chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1-carboxylate (TAK-242). | 2006-01 |
|
| Discovery of novel and potent small-molecule inhibitors of NO and cytokine production as antisepsis agents: synthesis and biological activity of alkyl 6-(N-substituted sulfamoyl)cyclohex-1-ene-1-carboxylate. | 2005-11-17 |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:21:53 GMT 2025
by
admin
on
Mon Mar 31 18:21:53 GMT 2025
|
| Record UNII |
H2MZ648C31
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C308
Created by
admin on Mon Mar 31 18:21:53 GMT 2025 , Edited by admin on Mon Mar 31 18:21:53 GMT 2025
|
||
|
FDA ORPHAN DRUG |
503515
Created by
admin on Mon Mar 31 18:21:53 GMT 2025 , Edited by admin on Mon Mar 31 18:21:53 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
11703255
Created by
admin on Mon Mar 31 18:21:53 GMT 2025 , Edited by admin on Mon Mar 31 18:21:53 GMT 2025
|
PRIMARY | |||
|
243984-11-4
Created by
admin on Mon Mar 31 18:21:53 GMT 2025 , Edited by admin on Mon Mar 31 18:21:53 GMT 2025
|
PRIMARY | |||
|
C87682
Created by
admin on Mon Mar 31 18:21:53 GMT 2025 , Edited by admin on Mon Mar 31 18:21:53 GMT 2025
|
PRIMARY | |||
|
100000175795
Created by
admin on Mon Mar 31 18:21:53 GMT 2025 , Edited by admin on Mon Mar 31 18:21:53 GMT 2025
|
PRIMARY | |||
|
C507035
Created by
admin on Mon Mar 31 18:21:53 GMT 2025 , Edited by admin on Mon Mar 31 18:21:53 GMT 2025
|
PRIMARY | |||
|
Resatorvid
Created by
admin on Mon Mar 31 18:21:53 GMT 2025 , Edited by admin on Mon Mar 31 18:21:53 GMT 2025
|
PRIMARY | |||
|
8785
Created by
admin on Mon Mar 31 18:21:53 GMT 2025 , Edited by admin on Mon Mar 31 18:21:53 GMT 2025
|
PRIMARY | |||
|
DTXSID00947269
Created by
admin on Mon Mar 31 18:21:53 GMT 2025 , Edited by admin on Mon Mar 31 18:21:53 GMT 2025
|
PRIMARY | |||
|
DB05943
Created by
admin on Mon Mar 31 18:21:53 GMT 2025 , Edited by admin on Mon Mar 31 18:21:53 GMT 2025
|
PRIMARY | |||
|
H2MZ648C31
Created by
admin on Mon Mar 31 18:21:53 GMT 2025 , Edited by admin on Mon Mar 31 18:21:53 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |